Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA

Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Preterm Neonates and Infants With Patent Ductus Arteriosus

The investigator's purpose is to study the population pharmacokinetics of paracatamol and ibuprofen in neonates with patent ductus arteriosus (PDA) and assess the feasibility of dosage individualization.

The investigator's purpose is to study the population pharmacokinetics of paracatamol and ibuprofen in neonates with patent ductus arteriosus (PDA) and assess the feasibility of dosage individualization. In this study, the investigator will detect drug concentration in plasma and other clinical test to construct population pharmacokinetic models.

Inclusion Criteria:

• Patients have been diagnosed with PDA;
• Age: postnatal age ≤ 28 days;
• Paracetamol or ibuprofen used as part of regular treatment;
• Paracetamol or ibuprofen was administered orally.

Exclusion Criteria:

• Patients who die within the treatment cycle;
• Patients with other heart diseases;
• Other factors that the researcher considers unsuitable for inclusion.